<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04481919</url>
  </required_header>
  <id_info>
    <org_study_id>190690</org_study_id>
    <nct_id>NCT04481919</nct_id>
  </id_info>
  <brief_title>Protocolized Diuretic Therapy Compared to Standard Care in Emergency Department Patients With Acute Heart Failure</brief_title>
  <official_title>A Randomized Trial of Protocolized Diuretic Therapy Compared to Standard Care in Emergency Department Patients With Acute Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized trial of protocolized diuretic therapy guided by urinary sodium compared&#xD;
      to structured usual care in ED patients with AHF. Participants will be recruited following an&#xD;
      initial standard evaluation in the ED and randomized in a 1:1 fashion to structured usual&#xD;
      care or protocolized diuretic therapy guided by urinary sodium.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A standardized protocol driven treatment pathway for hospitalized patients started in the&#xD;
      first few hours of ED evaluation and utilizing objective measures of diuretic response is&#xD;
      needed. The investigators believe this would maximize diuretic efficiency, facilitate quicker&#xD;
      resolution of congestion, avoid WHF and prolonged LOS, and reduce AHF readmissions. Propr&#xD;
      data suggests low urine sodium predicts length of stay and outcomes after initial diuretic&#xD;
      dosing in the outpatient and inpatient setting. Further, use of our pathway using spot urine&#xD;
      sodium to titrate subsequent loop diuretic doses and maximize response in inpatients with AHF&#xD;
      has shown compelling improvements in congestion and weight loss. However, a randomized trial&#xD;
      is necessary to determine if initiating this protocol ,started in the ED, will improve AHF&#xD;
      outcomes relative to structured usual care. Specifically, the investigators hypothesize use&#xD;
      of spot urine sodium guided diuretic therapy will: 1) result in significant improvement in&#xD;
      global clinical status at 5 days relative to structured usual care, and 2) result in&#xD;
      significant improvement in congestion at 5 days and in global rank at 30 days relative to&#xD;
      structured usual care. Early protocolized treatment of patients with AHF will more rapidly&#xD;
      improve dyspnea, avoid development of in-hospital WHF, result in greater decongestion at&#xD;
      hospital discharge, and therefore prevent HF-related readmissions and CV death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two-arm comparison of structured usual care vs urinary sodium guided diuresis</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Triple blinded study of guideline-based care compared with a protocolized diuretic strategy using urinary sodium</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Days of clinical benefit</measure>
    <time_frame>From randomization through day 14</time_frame>
    <description>Captures global clinical status, hospital days and death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in global clinical status (GCS)</measure>
    <time_frame>72 hours after randomization</time_frame>
    <description>Measured on the Likert scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Congestion</measure>
    <time_frame>72 hours after randomization</time_frame>
    <description>Based on the orthodema score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death and Readmission</measure>
    <time_frame>30 days</time_frame>
    <description>Cardiovascular death and Acute Heart Failure readmission</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Dyspnea score</measure>
    <time_frame>5 days after randomization or hospital discharge whichever comes first</time_frame>
    <description>VAS scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Congestion</measure>
    <time_frame>5 days after randomization or hospital discharge whichever comes first</time_frame>
    <description>Based on the orthodema score</description>
  </other_outcome>
  <other_outcome>
    <measure>Natriuretic peptide levels</measure>
    <time_frame>At hospital discharge and 7-day follow-up</time_frame>
    <description>Blood measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart Failure readmission and Cardiovascular death</measure>
    <time_frame>At 90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Readmission and all-cause death</measure>
    <time_frame>At 30 days and at 90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Differences in Epithelial Sodium Channel (ENaC) levels Web results Differences in Epithelial sodium channel (ENaC) levels</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>Between those with and without Worsening Heart Failure</description>
  </other_outcome>
  <other_outcome>
    <measure>Death and Readmission</measure>
    <time_frame>180 days</time_frame>
    <description>CV death and acute heart failure readmission</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Heart Failure</condition>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Protocolized spot urine sodium guided diuretic therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will have a spot urine sodium and urine creatinine obtained. The urine and creatinine results will be input into the diuretic calculator and the diuretic dose will be chosen based on daily goals for urine output and net negative fluid balance. Performed 3 times per day, diuretic dosing will be individualized based on the proportion of 24-hour diuresis achieved since the prior IV diuretic dose. Every 24 hours new goals for urine output and net negative fluid balance are established based on the study and treatment team's assessment of residual congestion until protocol completion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Guideline-based care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will be placed on guideline-based diuretic dosing consistent with usual practice. The initial dose will be two times their home dose and will be subsequently adjusted by the treating team based on renal function and symptom severity. The treating team can increase or decrease the frequency and dose of diuretic based on urine output and clinical assessment. Patients in this arm also have urine collected 3 times per day by the bedside nurse to mirror the intervention arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Protocolized diuretic therapy</intervention_name>
    <description>The urine sodium, urine creatinine and serum creatinine results will be input into the diuretic calculator and the diuretic dose will be chosen based on daily goals for urine output and net negative fluid balance.</description>
    <arm_group_label>Protocolized spot urine sodium guided diuretic therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Emergency Department diagnosis of Acute Heart Failure (AHF)&#xD;
&#xD;
          -  Any one of the following:&#xD;
&#xD;
             i. Chest radiograph or lung ultrasound consistent with AHF ii. Jugular venous&#xD;
             distension iii. Pulmonary rales on auscultation iv. Lower extremity edema v. S3 gallop&#xD;
&#xD;
          -  &gt; 10 pounds of volume overload physician estimate or historical dry weight&#xD;
&#xD;
          -  IV diuretic ordered or planned to be during first 24 hours of ED or inpatient stay&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  End Stage Renal Disease (ESRD) requiring dialysis&#xD;
&#xD;
          -  Need for immediate intubation&#xD;
&#xD;
          -  Acute Coronary Syndrome - presentation consistent with myocardial ischemia AND new&#xD;
             ST-Segment elevation/depression&#xD;
&#xD;
          -  Temperature &gt; 100.5ÂºF&#xD;
&#xD;
          -  End Stage Heart Failure: transplant list or ventricular assist device&#xD;
&#xD;
          -  Systolic Blood Pressure &lt; 90 mmHg at time of consent&#xD;
&#xD;
          -  LV outflow obstruction, severe uncorrected stenotic valvular disease or severe&#xD;
             restrictive cardiomyopathy&#xD;
&#xD;
          -  Greater than 2 doses of IV diuretic administered&#xD;
&#xD;
          -  Lack of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean P. Collins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sean P. Collins, MD</last_name>
    <phone>615-936-0253</phone>
    <email>sean.collins@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen F. Miller, RN</last_name>
    <phone>615-936-4790</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Tennessee Valley Health Service</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sean P. Collins, MD</last_name>
      <phone>615-936-0253</phone>
      <email>sean.collins@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Karen F. Miller, RN</last_name>
      <phone>615-936-4790</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sean P Collins, MD</last_name>
      <phone>615-936-0253</phone>
      <email>sean.collins@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Karen F. Miller, RN</last_name>
      <phone>615-936-4790</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 19, 2020</study_first_submitted>
  <study_first_submitted_qc>July 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Sean Collins</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Diuretic Therapy</keyword>
  <keyword>Emergency Department</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Publication Committee will authorize access to study data. Investigators must submit a proposal requesting approval to access our trial data. Our trial will participate in the NHLBI Central Repository for study data and specimens.&#xD;
All data access will follow guidelines described in the NHLBI Limited Access Data Policy.</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>The Publication Committee will authorize access to study data. Investigators must submit a proposal requesting approval to access our trial data. Our trial will participate in the NHLBI Central Repository for study data and specimens.&#xD;
All data access will follow guidelines described in the NHLBI Limited Access Data Policy</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

